Financial Performance - Revenue for the six months ended June 30, 2023, increased by 42.9% to RMB 109,586 thousand compared to RMB 76,713 thousand in the same period last year[26] - Gross profit rose by 56.7% to RMB 79,718 thousand, with gross margin improving by 6.4 percentage points to 72.7%[26] - The company's pre-tax loss decreased by 18.4% to RMB (54,636) thousand compared to RMB (66,985) thousand in the same period last year[26] - Revenue for the first half of 2023 reached RMB 109.6 million, a year-on-year increase of 42.9%, driven by strong sales of acute ischemic stroke (AIS) thrombectomy devices, intracranial artery stenosis treatment devices, and innovative access devices[28] - Gross profit increased by RMB 28.9 million, with the gross margin rising to 72.7%, while the sales, distribution, and administrative expense ratio decreased from 96.8% to 65.2%, narrowing the pre-tax loss to RMB 54.6 million[29] - Revenue increased by 42.9% from RMB 76.7 million in the six months ended June 30, 2022, to RMB 109.6 million in the six months ended June 30, 2023, driven by growth in sales of AIS thrombectomy devices, intracranial artery stenosis treatment devices, and innovative access devices[63] - Gross profit rose to RMB 79.7 million in the six months ended June 30, 2023, from RMB 50.9 million in the same period in 2022, with gross margin improving from 66.3% to 72.7% due to increased production and improved manufacturing processes[65] - Net loss narrowed to RMB 54,338 thousand in H1 2023, a 18.7% improvement from RMB 66,815 thousand in H1 2022[185] - Basic and diluted loss per share improved to RMB 1.42 in H1 2023 from RMB 1.75 in H1 2022[185] Product Development and Pipeline - The company's core product, Captor™ thrombectomy device, has been upgraded with nine different models and is being evaluated for new indications and overseas market expansion[13] - The intracranial drug-eluting balloon (DEB) has completed clinical trials and submitted for NMPA registration, with green channel qualification obtained[15] - The company has obtained NMPA approval for its embolic coils, which are used in the treatment of hemorrhagic stroke[16] - The company's spring coil embolization assist stent has completed clinical trials and submitted for NMPA registration, also with green channel qualification[17] - The company's left atrial appendage occluder, a core product for stroke prevention, received NMPA approval and began sales in the second half of 2022[19] - The company has 21 medical devices approved by the NMPA and 2 approved by the FDA, with several advanced pipelines, including drug-eluting balloons and flow diverters, in late-stage development[29][30] - The company’s pipeline includes products for acute ischemic stroke treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and interventional access, with a focus on expanding its product portfolio[31][43] Research and Development - R&D expenses for the reporting period amounted to RMB 69.9 million, focusing on advancing pipelines for stroke and pulmonary embolism treatment[29] - R&D costs increased to RMB 69.9 million in the six months ended June 30, 2023, from RMB 60.9 million in the same period in 2022, primarily due to higher raw material and consumable costs for trial production of pipeline products[67] - R&D expenses increased to RMB 69,850 thousand in H1 2023, up 14.7% from RMB 60,908 thousand in H1 2022[185] Sales and Distribution - The company has a broad sales network covering all provinces in China, excluding Hong Kong, Macau, and Taiwan[22] - The company’s sales network and hospital penetration strategy aim to enhance brand competitiveness in the Chinese neurointerventional market, leveraging the VBP and DRG/DIP payment reforms[28] - Sales and distribution expenses increased to RMB 41.7 million in the six months ended June 30, 2023, from RMB 36.0 million in the same period in 2022, driven by higher market development costs[86] Production and Operations - The company has three production bases in Shanghai and Nanjing, ensuring sufficient product supply[20] - The company’s production process optimization and cost-control measures have improved quality stability and operational efficiency[29] - As of June 30, 2023, the company’s contracted but not yet provided for plant and equipment amounted to RMB 9.11 million, compared to RMB 7.53 million at the end of 2022[40] Financial Position and Capital Expenditures - Cash and bank balances decreased to RMB 694.6 million as of June 30, 2023, from RMB 870.1 million as of December 31, 2022[70] - Capital expenditures totaled approximately RMB 47.2 million in the six months ended June 30, 2023, compared to RMB 23.8 million in the same period in 2022, mainly for the purchase of land use rights[90] - The company's net current assets stood at RMB 978.2 million as of June 30, 2023, down from RMB 1,064.5 million as of December 31, 2022[89] - The company's debt-to-equity ratio decreased to 3.9% as of June 30, 2023, from 4.3% as of December 31, 2022, with no outstanding borrowings as of June 30, 2023[88] Corporate Governance and Shareholder Information - The maximum number of H shares that can be granted under the 2021 H Share Incentive Plan is 3,000,000 H shares, representing approximately 9.5% of the company's H shares and 7.7% of the total issued share capital as of the report date[106] - As of January 1, 2023, and June 30, 2023, the total number of shares available for grant under the 2021 H Share Incentive Plan was 2,717,300 shares and 2,493,840 shares, respectively[106] - The company's global offering in 2021 raised a net amount of approximately HKD 1,014.8 million[109] - The company had 453 full-time employees as of June 30, 2023[116] - The 2021 H Share Incentive Plan allows for two types of awards: (i) three-year awards, which should be granted by December 31, 2024, and vest at the end of the third full fiscal year after grant (for up to 2,700,000 H shares), and (ii) one-year awards, which should vest by June 30 of the year following the grant year (with up to 100,000 H shares in 2022 and up to 300,000 H shares annually thereafter)[121] - The company has no significant contingent liabilities as of June 30, 2023[114] - The company faces foreign exchange risk due to bank cash denominated in USD and HKD, but currently has no foreign exchange hedging policy[115] - The 2021 H Share Incentive Plan is effective for ten years from November 1, 2021, and will remain in effect for any unvested awards granted before its expiration[120] - The company's directors and senior management's compensation policy is determined based on their responsibilities and market conditions, with discretionary and performance bonuses linked to the group's overall performance and individual performance[116] - The company's H shares were first listed on the Main Board of the Hong Kong Stock Exchange on August 20, 2021[109] - The company allocated HKD 459.7 million for the R&D, production, and marketing of its core products, with HKD 223.4 million utilized as of June 30, 2023, leaving a balance of HKD 236.3 million[129] - HKD 404.9 million was planned for the R&D and product registration of other pipeline products, with HKD 185.7 million utilized as of June 30, 2023, and a remaining balance of HKD 219.2 million[129] - HKD 48.7 million was fully utilized for enhancing R&D capabilities and expanding the product portfolio through internal research as of June 30, 2023[129] - HKD 101.5 million was allocated for working capital and general corporate purposes, fully utilized as of June 30, 2023[129] - The total funds raised from the IPO amounted to HKD 1,014.8 million, with HKD 559.3 million utilized as of June 30, 2023, and a remaining balance of HKD 455.5 million[129] - The company granted awards under the 2021 H Share Incentive Plan, with a fair value of approximately RMB 2.96 million, and 100% of the awards will vest by December 31, 2025, subject to performance conditions[150] - The company's independent auditor, Ernst & Young, reviewed the interim financial information for the six months ended June 30, 2023, in accordance with Hong Kong Standard on Review Engagements 2410[135] - The company's directors and senior management held significant equity interests, with Wang Guohui holding 8.21% of non-listed shares and 20.99% of H shares as of June 30, 2023[144] - The company did not purchase, sell, or redeem any of its listed securities during the six months ended June 30, 2023[130] - The company adopted the Standard Code as the code of conduct for directors, supervisors, and senior management regarding the trading of the company's securities[131] - The company does not recommend paying an interim dividend for the six months ended June 30, 2023 (no interim dividend was paid for the six months ended June 30, 2022)[153] - The company's Board of Directors and senior management have complied with the standard code of securities transactions during the six months ended June 30, 2023[154] - Wang Guohui serves as both the Chairman and CEO of the company, deviating from the corporate governance code, but the Board believes this structure enhances leadership and strategic planning efficiency[156] - The Audit Committee and management confirm that the interim financial results for the six months ended June 30, 2023 comply with relevant accounting standards and regulations[157] - Feng Xiangqian was appointed as the Chairman of the Nomination Committee, effective March 20, 2023[159] - Wang Guohui directly holds 1,915,690 non-listed shares and 1,915,690 H shares, with additional interests through related entities[169] - Zhang Yanxia holds 3,188,110 non-listed shares (8.21%) and 8,152,618 H shares (20.99%) through spousal interests[171] - Shanghai Zandaqian Enterprise Management Consulting Center holds 496,183 non-listed shares (1.28%) and 4,777,225 H shares (12.30%) through controlled corporation interests[171] - Ningbo Meishan Bonded Port Area Xinwei Investment Management Partnership holds 776,237 non-listed shares (2.00%) and 1,459,703 H shares (3.76%) as beneficial owner[171] - Ningbo Meishan Bonded Port Area Kaiyuan Investment Management Partnership holds 1,277,192 H shares (3.29%) as beneficial owner[171] - Shanghai Weijun Enterprise Management Consulting Partnership holds 2,800,000 H-shares, representing 7.21% of the total issued shares[174] - Chai Yanpeng holds 1,566,488 non-listed shares, representing 4.03% of the total issued shares[174] - Ningbo Tongchuang Suwei Investment Partnership holds 869,330 non-listed shares, representing 2.24% of the total issued shares[174] - SDIC Chuanghe National Emerging Industry Venture Capital Fund holds 906,220 non-listed shares, representing 2.33% of the total issued shares[174] - Temasek Life Sciences Private Limited holds 1,627,907 H-shares, representing 4.19% of the total issued shares[174] - LYFE Columbia River Limited holds 152,599 non-listed shares, representing 0.39% of the total issued shares[174] - LYFE Ohio River Limited holds 49,147 non-listed shares, representing 0.13% of the total issued shares[174] - Raritan River Limited holds 65,116 non-listed shares, representing 0.17% of the total issued shares[174] - LYFE Capital Fund III (Dragon), L.P. holds 201,746 non-listed shares, representing 0.52% of the total issued shares[174] - LYFE Capital Management Limited holds 13.64% of H-shares and 0.69% of non-listed shares[198] - LYFE Columbia River Limited directly holds 2,899,373 H-shares and 152,599 non-listed shares[199] - LYFE Ohio River Limited directly holds 933,784 H-shares and 49,147 non-listed shares[199] - Raritan River Limited directly holds 1,237,210 H-shares and 65,116 non-listed shares[199] - LYFE Capital Fund III (Dragon), L.P. directly holds 227,300 H-shares[199] Audit and Compliance - The interim financial report for 2023 has been reviewed and no material misstatements were found according to International Accounting Standard 34[183] - The company's independent auditor, Ernst & Young, reviewed the interim financial information for the six months ended June 30, 2023, in accordance with Hong Kong Standard on Review Engagements 2410[135] - The Audit Committee and management confirm that the interim financial results for the six months ended June 30, 2023 comply with relevant accounting standards and regulations[157] Strategic Plans and Market Expansion - The company plans to expand its brand as a comprehensive neurointerventional device provider, improve manufacturing capabilities, and develop innovative medical devices in high-growth potential markets[62] - Overseas revenue increased following the approval of multiple products by local regulatory authorities, supported by a broad sales network covering all provinces in mainland China, excluding Hong Kong, Macau, and Taiwan[28]

8. 股息 於各報告期末，貿易應收款項按發票日期及扣除虧損撥備的賬齡分析如下： 因應VBP政策及DRG/DIP支付方式改革量回升手術量回升及進口替代加速， 我們持續利用高效的銷售渠道提高醫院滲透率及提高醫生對我們產品的 認可度，旨在通過覆蓋香港、澳門及台灣以外的所有省份的廣泛銷售網絡 提高我們於中國神經介入市場的品牌競爭力。同時，當地藥監局批准我們 多款產品註冊後，海外收益有所提振。 我們最終未必能夠就Captor成功開發新的適應症及規格並擴大海外市場。 核心產品 — 左心耳封堵器是永久性植入非瓣膜性房顫(AF)患者左心耳開 口處的腦卒中預防器械，以防止左心耳血栓分離，引起栓塞。左心耳封堵 手術為療效確切的單次手術治療方案，尤其適用於不適合長期口服抗凝 治療且出血性併發症風險較高的患者。我們已取得NMPA批文，並於2022 年下半年開始銷售。 我們矢志成為中國神經介入醫療器械市場的領導者，並成為中國多款創 新醫療器械市場中具競爭力的國產器械公司。 銷售成本 財務成本 外匯風險 董事會不建議派付截至2023年6月30日止六個月的中期股息（截至2022年6月30 日止六個月：無）。 審計委員會與本公司管理層認為截 ...

2022 ANNUAL REPORT 年度報告 ANNUAL REPORT 2022 年度報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務概要 | 4 | | 董事長致辭 | 5 | | 管理層討論及分析 | 7 | | 董事、監事及高級管理層 | 18 | | 企業管治報告 | 26 | | 環境、社會及管治報告 | 46 | | 董事會報告 | 73 | | 監事會報告 | 93 | | 獨立核數師報告 | 95 | | 綜合損益及其他全面收益表 | 102 | | 綜合財務狀況表 | 103 | | 綜合權益變動表 | 105 | | 綜合現金流量表 | 106 | | 財務報表附註 | 108 | | 釋義 | 177 | 2 上海心瑋醫療科技股份有限公司 公司資料 董事會 執行董事 王國輝先生 （董事長、首席執行官） 張坤女士 （副總經理） 韋家威先生 （副總經理，於2022年6月10日獲委任） 非執行董事 丁魁先生 歐陽翔宇先生 （於2022年7月15日辭任） 陳剛先生 （於2022年8月31日辭任） 陳少雄先生 （於2022年11月9日獲委任） 獨立非執行董事 郭少牧先 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6609） 截至2022年12月31日止年度 全年業績公告 財務概要 截至2022年 截至2021年 12月31日 12月31日 止年度 止年度 同比變動 人民幣千元 人民幣千元 收益 183,032 90,089 103.2% 毛利 124,333 54,950 126.3% 毛利率 67.9% 61.0% 6.9個百分點 研發成本 153,693 76,306 101.4% ...

上海心瑋醫療科技股份有限公司 Shanghai HeartCare Medical Technology Corporation Limited (A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) Stock Code 股份代號：6609 d ur LOO D 2 25 D INTERIM REPORT 中期報告 0 L ( ■] □] 0 L C 目錄 | --- | --- | |----------------------------------|-------| | | | | 公司資料 | 2 | | 財務摘要 | 4 | | 管理層討論及分析 | 5 | | 企業管治及其他資料 | 15 | | 獨立審閱報告 | 23 | | 中期簡明綜合損益及其他全面收益表 | 24 | | 中期簡明綜合財務狀況表 | 25 | | 中期簡明綜合權益變動表 | 27 | | 中期簡明綜合現金流量表 | 28 | | 中期簡明綜合財務資 ...

Financial Performance - Revenue for 2021 reached RMB 90.1 million, a significant increase of 517% compared to RMB 14.6 million in 2020[9][11] - Gross profit for 2021 was RMB 54.95 million, up from RMB 7.087 million in 2020[9] - The company reported a net loss of RMB 197.906 million in 2021, compared to a net loss of RMB 216.183 million in 2020[9] - Total non-current assets increased to RMB 172.324 million in 2021 from RMB 111.849 million in 2020[9] - Total current assets rose to RMB 1.332 billion in 2021 from RMB 661.782 million in 2020[9] - Total equity increased to RMB 1.373 billion in 2021 from RMB 691.035 million in 2020[9] - Gross margin improved from 49% in 2020 to 61% in 2021 due to increased production and corresponding economies of scale[41] - R&D costs increased from RMB 51.1 million in 2020 to RMB 76.3 million in 2021, primarily due to increased R&D expenses for in-development medical devices[45] - Administrative expenses decreased to RMB 83.9 million in 2021 from RMB 141.9 million in 2020, primarily due to reduced share-based compensation expenses[47] - Sales and distribution expenses rose to RMB 51.1 million in 2021, a 257.3% increase from RMB 14.3 million in 2020, driven by sales team expansion[48] - Cash and bank balances surged 92.6% to RMB 1,217.7 million in 2021, primarily due to proceeds from the global offering[53] - Capital expenditures totaled RMB 54.5 million in 2021, used for purchasing equipment, machinery, and software[53] - Employee benefits expenses decreased to RMB 114.3 million in 2021 from RMB 157.9 million in 2020, mainly due to reduced share-based compensation[60] - The company allocated RMB 59.0 million of the global offering proceeds for core product R&D, production, and marketing, with RMB 400.7 million remaining[57] - The company's audit fees for the fiscal year ending December 31, 2021, amounted to approximately RMB 8.58 million, with non-audit service fees for internal control review totaling RMB 0.45 million[167] - Total fees paid or payable to the auditor for audit and non-audit services for the fiscal year ending December 31, 2021, were RMB 9.03 million, including RMB 3.9 million for annual audit services and RMB 4.68 million for IPO services[168] Market Expansion and Sales - The company's full suite of thrombectomy devices has achieved market access in almost all provinces in China, covering approximately 1,400 hospitals across 31 provinces[11] - The company established a sales network including over 100 distributors and more than 100 sales personnel[11] - Revenue from commercialized neurointerventional devices reached RMB 90.1 million in 2021, supported by a sales network covering 31 provinces[17] - The company's sales and marketing team consists of over 100 employees, with a distribution network covering more than 1,400 hospitals across 31 provinces in China[36] - The company's revenue increased by 517% from RMB 14.6 million in 2020 to RMB 90.1 million in 2021, driven by sales of ischemic stroke thrombectomy devices and intracranial artery stenosis treatment devices[39] Product Development and Innovation - The company's neurovascular stenosis treatment product portfolio, approved in 2021, contributed to the revenue growth[11] - The company has obtained NMPA approval for 11 neurointerventional devices, covering three major surgical procedures and neurointerventional access devices[12] - Two products have received FDA 510K certification, marking the company's entry into the international market[12] - The company has approximately 20 emerging product pipelines in development, including left atrial appendage occluders and electrophysiology devices[13] - The company has 3 neurointerventional products in clinical trials and 4 under registration review[18] - Core product Captor™ thrombectomy device, the first multi-point imaging thrombectomy stent approved by NMPA in China, has been upgraded with 9 different models for various vessel diameters and thrombus sizes[25] - The company plans to expand Captor's indications and explore overseas marketing opportunities, potentially applying for registration in the US and Europe[25] - The company expects to obtain NMPA approval for its left atrial appendage occluder in Q2 2022 and begin sales in the second half of 2022[30] - The company has developed a comprehensive neurointerventional product portfolio, including 11 NMPA-approved products and a broad pipeline[19] - The company is advancing multiple innovative medical device pipelines in lung intervention and computer-assisted technology fields[13] - The company plans to expand its product portfolio in the cardiac intervention field, including robotic-assisted coronary intervention[13] Corporate Governance and Leadership - The company successfully listed on the Hong Kong Stock Exchange on August 20, 2021 (Stock Code: 6609)[9][11] - The company has adopted the Corporate Governance Code of the Hong Kong Stock Exchange (HKEX) and will apply the new version effective from January 1, 2022, for the fiscal year ending December 31, 2022[114] - The Chairman and CEO roles are combined, held by Mr. Wang Guohui, which deviates from the Corporate Governance Code but is deemed beneficial for leadership consistency and strategic efficiency[116] - The Board of Directors consists of 2 executive directors, 3 non-executive directors, and 3 independent non-executive directors, ensuring a high level of independence[122] - The company held 2 Audit Committee meetings and 2 Remuneration Committee meetings from the listing date to December 31, 2021[115] - The Chairman intends to hold at least one annual meeting with independent non-executive directors without the presence of other directors, as per the Corporate Governance Code[120] - All directors and supervisors confirmed compliance with the Model Code for Securities Transactions from the listing date to December 31, 2021[121] - The company has a Nomination Committee that evaluates the skills, knowledge, and experience required for the Board and recommends suitable candidates[127] - The company’s Board Diversity Policy is considered when evaluating and determining director candidates[130] - The company has received annual written confirmations of independence from all independent non-executive directors[125] - The company’s directors are elected for a term of three years and can be re-elected or removed by ordinary resolution[127] - The company has established three board committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with defined responsibilities and sufficient resources to fulfill their duties[131][137] - The Audit Committee, chaired by Mr. Gong Ping, consists of one non-executive director and two independent non-executive directors, and held 2 meetings during the reporting period[138][139] - The Remuneration Committee, chaired by Mr. Guo Shaomu, consists of one executive director and two independent non-executive directors, and held 2 meetings to review the 2021 H-share incentive plan and related grant schemes[141][143] - The Nomination Committee, chaired by Mr. Wang, consists of one executive director and two independent non-executive directors, and did not hold any meetings during the reporting period[145][146] - The company has adopted a Board Diversity Policy to enhance the effectiveness of the Board and maintain high standards of corporate governance, considering factors such as gender, age, culture, educational background, and professional experience[149] - The company has arranged appropriate insurance coverage for directors, supervisors, and senior management to protect them against legal actions arising from company affairs, with the coverage reviewed annually[133] - All directors are required to participate in continuous professional development to update their knowledge and skills, and are encouraged to attend relevant training courses at the company's expense[135] - The company's senior management, including 2 directors, had a total of 5 members with annual remuneration ranging from RMB 1 million to RMB 30 million in 2021[144] - The Audit Committee reviewed the company's 2021 interim report and annual audit plan during the reporting period[140] - The Remuneration Committee is responsible for recommending the remuneration policy and structure for all directors and senior management, and determining their specific remuneration packages[141] - The company aims to achieve a target of 20% female representation on the board by actively seeking qualified female candidates[150] - The company held 6 board meetings, 2 audit committee meetings, and 2 remuneration committee meetings from the listing date to December 31, 2021[158] - All directors attended all 6 board meetings during the period from the listing date to December 31, 2021[160] - The company held one extraordinary general meeting on November 1, 2021, attended by Mr. Wang Guohui and Mr. Ding Kui[162] - The board is responsible for ensuring the timely publication of the company's financial statements and preparing them on a going concern basis[166] ESG and Sustainability - The company has integrated sustainable development concepts into its daily operations, aligning its overall strategic direction with sustainable development goals[192] - The company aims to become a leader in the domestic neurointervention market by providing a one-stop solution for stroke treatment and prevention[195] - In 2021, the company received multiple honors, including being recognized as a high-tech enterprise and a "Specialized, Refined, and Innovative" small and medium-sized enterprise in Shanghai[196] - The company actively communicates with stakeholders, including shareholders, customers, employees, suppliers, government and regulatory agencies, and the community, to understand their expectations and opinions on sustainable development[197] - High importance issues identified for the company's ESG (Environmental, Social, and Governance) reporting[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] - Medium importance issues identified for the company's ESG reporting[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] - Low importance issues identified for the company's ESG reporting[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] - Importance matrix established based on stakeholder input and business significance assessment[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] Risk Management and Internal Controls - The company's internal audit department is responsible for identifying and assessing major risks across operations and monitoring the correction of internal control deficiencies[185] - The internal audit department reviewed the effectiveness of internal controls related to major business processes, identified gaps and improvement opportunities, and recommended corrective actions. No significant internal control system deficiencies were identified[186] - The company has established a monitoring system to accept complaints and reports regarding violations by employees and external distributors and suppliers[189] - The Board of Directors reviewed the risk management and internal control systems for the year ended December 31, 2021, and found them to be effective and adequate[190] - The company has implemented anti-corruption and anti-bribery compliance training for directors, senior management, and sales employees to enhance their understanding and compliance with applicable laws and regulations[186] Leadership and Key Personnel - The company's executive director, Mr. Wang Guohui, has over 20 years of experience in medical device R&D and commercialization, previously holding key roles at leading medical technology companies[72][73] - The company's executive director, Ms. Zhang Kun, has over 20 years of experience in medical device R&D and commercialization, with a focus on clinical trials and cardiac intervention business[75][76] - The company's non-executive director, Mr. Ding Kui, has over 15 years of experience in finance and the medical industry, currently serving as Vice President and Board Secretary of Shanghai Kinetic Medical Co., Ltd[78] - Chen Gang joined the company as a director in June 2020 and was re-designated as a non-executive director in November 2020, providing strategic advice on operations and management[81] - Chen Gang has over 14 years of experience in the financial industry, including roles at L.E.K. Consulting and Vivo Capital, focusing on business strategy and M&A for healthcare and life sciences clients[81] - Chen Gang has held various positions in companies such as Shanghai Alland Biotech, CoreCatch Medical, and Sinomed, contributing to international business development and board roles[82] - Chen Gang currently serves as a director for multiple external companies, including Beijing Anzhiyin Biotech and Shanghai GenScript Biotech, focusing on biopharmaceutical CDMO services[83] - Ouyang Xiangyu joined the company as a director in June 2020 and was re-designated as a non-executive director in November 2020, providing strategic advice on operations and management[84] - Ouyang Xiangyu has extensive experience in the high-tech and financial industries, including roles at Legend Capital and founding Sharlyn Capital in 2018[85] - Guo Shaomu has over 13 years of experience in Hong Kong investment banking, including roles at Salomon Smith Barney, HSBC Markets, J.P. Morgan, and Morgan Stanley, focusing on financial services and real estate markets[89] - Guo Shaomu currently serves as an independent non-executive director for several listed companies, including Yida China Holdings and Fantasia Holdings Group[90] - Feng Xiangqian joined the company as an independent non-executive director in November 2020, providing independent opinions on operations and management[93] - Feng Xiangqian has over 14 years of experience in the financial industry, including roles at Caitong Securities, Donghai Securities, and Shenzhen Stock Exchange, focusing on IPO and investment banking[93] - Gong Ping, aged 35, has been serving as an independent non-executive director since January 11, 2021, providing independent opinions on the company's operations and management[94] - Zhou Baolei, aged 36, joined the company in September 2019 and was appointed as a supervisor on November 23, 2020, responsible for overseeing the company's operations[96] - Mei Jianghua, aged 44, joined the company in September 2019 and was appointed as a supervisor on November 23, 2020, responsible for overseeing the company's operations[96] - Xing Tingyu, aged 36, joined the company in August 2019 and was appointed as an employee supervisor on November 23, 2020, responsible for representing employees in overseeing the company's operations[98] - Wang Guohui, aged 44, has been serving as the CEO since the company's establishment in June 2016 and was appointed as the Chairman on November 23, 2020[100] - Li Zhigang, aged 60, has been serving as the Vice President since November 2020, responsible for the company's R&D management[101] - Wei Jiawei, aged 44, joined the company in September 2020 and was appointed as Vice President on November 23, 2020, responsible for the company's sales management[104] - Zhang Han, aged 35, joined the company in November 2020 and was appointed as CFO on November 23, 2020, responsible for the company's strategic development and financial management[107] Shareholder Communication and Investor Relations - The company has established multiple communication channels with shareholders, investors, and other stakeholders, including the publication of interim and annual reports, shareholder meetings, and online resources[181] - The company has no immediate plans to declare or pay any dividends, as it intends to retain all future earnings for business operations and expansion[182] Strategic Goals and Future Plans - The company aims to enhance its brand competitiveness and market share in the neurointerventional market in the coming years[14] - The company aims to become a leader in China's neurointerventional medical device market and develop a competitive product portfolio in the cardiac intervention market[38] - The company plans to expand manufacturing facilities in the Lingang New Area to meet growing product demand[34] - A new production facility in Shanghai's Lingang area has obtained medical device production licenses to ensure stable supply[17] Intellectual Property and Patents - The company has 50 registered patents in China, including 13 invention patents, 36 utility model patents, and 1 design patent, with 124 pending patent applications[32] Share Incentive Plans and Equity Transactions - The company implemented the 2021 H Share Incentive Plan, with a maximum of 750,000 H shares available for acquisition by the trustee[62] - The 2021 H Share Incentive Plan will be funded by the company's internal resources and not from the global offering proceeds[64] - The company purchased a total of 274,450 shares under the 2021 H-share incentive plan at an average price of HKD 94 per share, with a total cost of approximately HKD 25.8 million (excluding brokerage commissions and other expenses)[65] - Under the 2021 H-share incentive plan, the company granted 386,700 shares to employees in January 2022[68] - The company's shares were purchased under the 2021 H-share incentive plan on the Hong Kong Stock Exchange for a total consideration of RMB 14.813 million (excluding expenses)[67] Acquisitions and Investments - The company acquired a 36% equity stake in Shanghai Yuban Medical Technology Co., Ltd. for a total consideration of RMB 34.8 million, with RMB 4.8 million paid in March 2022[67] - The company's subsidiary, Shanghai Weiqi Medical Device Co., Ltd., entered into an agreement to acquire equity and inject capital into Shanghai Yuban Medical Technology Co., Ltd[67] - The company has not authorized any significant investment or capital asset acquisition plans as of the report date[66] Foreign Exchange Risk - The company faces foreign exchange risk due to bank cash denominated in USD and HKD, with no current foreign currency hedging policy in place[69]

上海心瑋醫療科技股份有限公司 Shanghai HeartCare Medical Technology Corporation Limited (A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) Stock Code 股份代號：6609 2021 INTERIM REPORT 中期報告 目錄 公司資料 2 財務摘要 4 管理層討論及分析 5 企業管治及其他資料 16 獨立審閱報告 26 中期簡明綜合損益及其他全面收益表 27 中期簡明綜合財務狀況表 28 中期簡明綜合權益變動表 30 中期簡明綜合現金流量表 31 中期簡明綜合財務資料附註 33 釋義 43 2 上海心瑋醫療科技股份有限公司 公司資料 | --- | --- | |----------------------------------------------------|-------------------| | | | | 中文名稱 | 香港主要營業地點 | | ...